Prophylactic Radiotherapy to Prevent Bone Complications in Metastatic Solid Cancers NCT07540650
Summary
NIH registered a new prospective, randomized, single-center Phase 2 clinical trial (NCT07540650) to evaluate whether early prophylactic radiotherapy to high-risk asymptomatic or minimally symptomatic bone metastases reduces the 1-year rate of skeletal-related events in patients with metastatic solid cancers. Patients will be randomized 1:1 to receive either standard of care systemic therapy or observation, or prophylactic radiotherapy plus standard of care. The primary endpoint is the 1-year rate of skeletal-related events; secondary endpoints include adverse events, quality of life, economic burden, pain-free survival, and overall survival.
What changed
NIH added a new Phase 2 clinical trial (NCT07540650) to the ClinicalTrials.gov registry. The trial enrolls patients with metastatic solid cancers and bone metastases, randomizing them 1:1 to standard of care or prophylactic external beam radiotherapy plus standard of care.
Healthcare providers, clinical investigators, and patients considering trial participation should review the eligibility criteria and randomization schedule. This registry entry does not create compliance obligations; it documents an ongoing research program.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Prophylactic Radiotherapy to Prevent Bone Complications in Patients With Metastatic Solid Cancers
Phase 2 NCT07540650 Kind: PHASE2 Apr 20, 2026
Abstract
This is a prospective, randomized, single-center clinical trial evaluating whether early prophylactic radiotherapy to high-risk asymptomatic or minimally symptomatic bone metastases reduces the 1-year rate of skeletal-related events (SREs) in patients with metastatic solid cancers. Patients will be randomized in a 1:1 ratio to receive either standard of care systemic therapy or observation, or prophylactic radiotherapy in addition to standard of care. The primary endpoint is the 1-year rate of SREs. Secondary endpoints include adverse events, quality of life, economic burden, pain-free survival, and overall survival.
Conditions: Bone Metastases, Metastatic Solid Tumor
Interventions: Prophylactic External Beam Radiotherapy, Standard of Care
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.